Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 172

1.

Transcriptomic abnormalities in peripheral blood in bipolar disorder, and discrimination of the major psychoses.

Hess JL, Tylee DS, Barve R, de Jong S, Ophoff RA, Kumarasinghe N, Tooney P, Schall U, Gardiner E, Beveridge NJ, Scott RJ, Yasawardene S, Perera A, Mendis J, Carr V, Kelly B, Cairns M; Neurobehavioural Genetics Unit, Tsuang MT, Glatt SJ.

Schizophr Res. 2019 Aug 4. pii: S0920-9964(19)30316-0. doi: 10.1016/j.schres.2019.07.036. [Epub ahead of print]

PMID:
31391148
2.

HoxA9 binds and represses the Cebpa +8 kb enhancer.

Peng L, Guo H, Ma P, Sun Y, Dennison L, Aplan PD, Hess JL, Friedman AD.

PLoS One. 2019 May 23;14(5):e0217604. doi: 10.1371/journal.pone.0217604. eCollection 2019.

3.

Genetic correlations among psychiatric and immune-related phenotypes based on genome-wide association data.

Tylee DS, Sun J, Hess JL, Tahir MA, Sharma E, Malik R, Worrall BB, Levine AJ, Martinson JJ, Nejentsev S, Speed D, Fischer A, Mick E, Walker BR, Crawford A, Grant SFA, Polychronakos C, Bradfield JP, Sleiman PMA, Hakonarson H, Ellinghaus E, Elder JT, Tsoi LC, Trembath RC, Barker JN, Franke A, Dehghan A; 23 and Me Research Team; Inflammation Working Group of the CHARGE Consortium; METASTROKE Consortium of the International Stroke Genetics Consortium; Netherlands Twin Registry; neuroCHARGE Working Group; Obsessive Compulsive and Tourette Syndrome Working Group of the Psychiatric Genomics Consortium, Faraone SV, Glatt SJ.

Am J Med Genet B Neuropsychiatr Genet. 2018 Oct;177(7):641-657. doi: 10.1002/ajmg.b.32652. Epub 2018 Oct 16.

PMID:
30325587
4.

HOXA9 Reprograms the Enhancer Landscape to Promote Leukemogenesis.

Sun Y, Zhou B, Mao F, Xu J, Miao H, Zou Z, Phuc Khoa LT, Jang Y, Cai S, Witkin M, Koche R, Ge K, Dressler GR, Levine RL, Armstrong SA, Dou Y, Hess JL.

Cancer Cell. 2018 Oct 8;34(4):643-658.e5. doi: 10.1016/j.ccell.2018.08.018. Epub 2018 Sep 27.

PMID:
30270123
5.

An integrated analysis of genes and functional pathways for aggression in human and rodent models.

Zhang-James Y, Fernàndez-Castillo N, Hess JL, Malki K, Glatt SJ, Cormand B, Faraone SV.

Mol Psychiatry. 2018 Jun 1. doi: 10.1038/s41380-018-0068-7. [Epub ahead of print]

6.

Why is there selective subcortical vulnerability in ADHD? Clues from postmortem brain gene expression data.

Hess JL, Akutagava-Martins GC, Patak JD, Glatt SJ, Faraone SV.

Mol Psychiatry. 2018 Aug;23(8):1787-1793. doi: 10.1038/mp.2017.242. Epub 2017 Nov 28.

PMID:
29180674
7.

PTSD Blood Transcriptome Mega-Analysis: Shared Inflammatory Pathways across Biological Sex and Modes of Trauma.

Breen MS, Tylee DS, Maihofer AX, Neylan TC, Mehta D, Binder EB, Chandler SD, Hess JL, Kremen WS, Risbrough VB, Woelk CH, Baker DG, Nievergelt CM, Tsuang MT, Buxbaum JD, Glatt SJ.

Neuropsychopharmacology. 2018 Feb;43(3):469-481. doi: 10.1038/npp.2017.220. Epub 2017 Sep 19.

8.

Neuregulin-1 (NRG1) polymorphisms linked with psychosis transition are associated with enlarged lateral ventricles and white matter disruption in schizophrenia.

Bousman CA, Cropley V, Klauser P, Hess JL, Pereira A, Idrizi R, Bruggemann J, Mostaid MS, Lenroot R, Weickert TW, Glatt SJ, Everall IP, Sundram S, Zalesky A, Weickert CS, Pantelis C.

Psychol Med. 2018 Apr;48(5):801-809. doi: 10.1017/S0033291717002173. Epub 2017 Aug 22.

PMID:
28826413
9.

A Systematic Literature Review of US Engineering Ethics Interventions.

Hess JL, Fore G.

Sci Eng Ethics. 2018 Apr;24(2):551-583. doi: 10.1007/s11948-017-9910-6. Epub 2017 Apr 11.

PMID:
28401510
10.

Genetics of Schizophrenia: Historical Insights and Prevailing Evidence.

van de Leemput J, Hess JL, Glatt SJ, Tsuang MT.

Adv Genet. 2016;96:99-141. doi: 10.1016/bs.adgen.2016.08.001. Epub 2016 Sep 27. Review.

PMID:
27968732
11.

Blood transcriptomic comparison of individuals with and without autism spectrum disorder: A combined-samples mega-analysis.

Tylee DS, Hess JL, Quinn TP, Barve R, Huang H, Zhang-James Y, Chang J, Stamova BS, Sharp FR, Hertz-Picciotto I, Faraone SV, Kong SW, Glatt SJ.

Am J Med Genet B Neuropsychiatr Genet. 2017 Apr;174(3):181-201. doi: 10.1002/ajmg.b.32511. Epub 2016 Nov 11.

12.

A new target for differentiation therapy in AML.

Ma P, Song W, Hess JL.

Cell Res. 2017 Jan;27(1):9-10. doi: 10.1038/cr.2016.130. Epub 2016 Nov 11.

13.

RNA sequencing of transformed lymphoblastoid cells from siblings discordant for autism spectrum disorders reveals transcriptomic and functional alterations: Evidence for sex-specific effects.

Tylee DS, Espinoza AJ, Hess JL, Tahir MA, McCoy SY, Rim JK, Dhimal T, Cohen OS, Glatt SJ.

Autism Res. 2017 Mar;10(3):439-455. doi: 10.1002/aur.1679. Epub 2016 Aug 16.

PMID:
27529825
14.

Transcriptome-wide mega-analyses reveal joint dysregulation of immunologic genes and transcription regulators in brain and blood in schizophrenia.

Hess JL, Tylee DS, Barve R, de Jong S, Ophoff RA, Kumarasinghe N, Tooney P, Schall U, Gardiner E, Beveridge NJ, Scott RJ, Yasawardene S, Perera A, Mendis J, Carr V, Kelly B, Cairns M; Neurobehavioural Genetics Unit, Tsuang MT, Glatt SJ.

Schizophr Res. 2016 Oct;176(2-3):114-124. doi: 10.1016/j.schres.2016.07.006. Epub 2016 Jul 20.

15.

SLC9A9 Co-expression modules in autism-associated brain regions.

Patak J, Hess JL, Zhang-James Y, Glatt SJ, Faraone SV.

Autism Res. 2017 Mar;10(3):414-429. doi: 10.1002/aur.1670. Epub 2016 Jul 21.

PMID:
27439572
16.

Deregulation of the HOXA9/MEIS1 axis in acute leukemia.

Collins CT, Hess JL.

Curr Opin Hematol. 2016 Jul;23(4):354-61. doi: 10.1097/MOH.0000000000000245. Review.

17.

PRDM16 Suppresses MLL1r Leukemia via Intrinsic Histone Methyltransferase Activity.

Zhou B, Wang J, Lee SY, Xiong J, Bhanu N, Guo Q, Ma P, Sun Y, Rao RC, Garcia BA, Hess JL, Dou Y.

Mol Cell. 2016 Apr 21;62(2):222-236. doi: 10.1016/j.molcel.2016.03.010. Epub 2016 Apr 14.

18.

The influence of genes on "positive valence systems" constructs: A systematic review.

Hess JL, Kawaguchi DM, Wagner KE, Faraone SV, Glatt SJ.

Am J Med Genet B Neuropsychiatr Genet. 2016 Jan;171B(1):92-110. doi: 10.1002/ajmg.b.32382. Epub 2015 Sep 14. Review.

PMID:
26365619
19.

A splicing-regulatory polymorphism in DRD2 disrupts ZRANB2 binding, impairs cognitive functioning and increases risk for schizophrenia in six Han Chinese samples.

Cohen OS, Weickert TW, Hess JL, Paish LM, McCoy SY, Rothmond DA, Galletly C, Liu D, Weinberg DD, Huang XF, Xu Q, Shen Y, Zhang D, Yue W, Yan J, Wang L, Lu T, He L, Shi Y, Xu M, Che R, Tang W, Chen CH, Chang WH, Hwu HG, Liu CM, Liu YL, Wen CC, Fann CS, Chang CC, Kanazawa T, Middleton FA, Duncan TM, Faraone SV, Weickert CS, Tsuang MT, Glatt SJ.

Mol Psychiatry. 2016 Jul;21(7):975-82. doi: 10.1038/mp.2015.137. Epub 2015 Sep 8.

PMID:
26347318
20.

Role of HOXA9 in leukemia: dysregulation, cofactors and essential targets.

Collins CT, Hess JL.

Oncogene. 2016 Mar 3;35(9):1090-8. doi: 10.1038/onc.2015.174. Epub 2015 Jun 1. Review.

21.

Pharmacologic inhibition of the Menin-MLL interaction blocks progression of MLL leukemia in vivo.

Borkin D, He S, Miao H, Kempinska K, Pollock J, Chase J, Purohit T, Malik B, Zhao T, Wang J, Wen B, Zong H, Jones M, Danet-Desnoyers G, Guzman ML, Talpaz M, Bixby DL, Sun D, Hess JL, Muntean AG, Maillard I, Cierpicki T, Grembecka J.

Cancer Cell. 2015 Apr 13;27(4):589-602. doi: 10.1016/j.ccell.2015.02.016. Epub 2015 Mar 26.

22.

Bioinformatic analyses and conceptual synthesis of evidence linking ZNF804A to risk for schizophrenia and bipolar disorder.

Hess JL, Quinn TP, Akbarian S, Glatt SJ.

Am J Med Genet B Neuropsychiatr Genet. 2015 Jan;168B(1):14-35. doi: 10.1002/ajmg.b.32284. Review.

PMID:
25522715
23.

The same site on the integrase-binding domain of lens epithelium-derived growth factor is a therapeutic target for MLL leukemia and HIV.

Murai MJ, Pollock J, He S, Miao H, Purohit T, Yokom A, Hess JL, Muntean AG, Grembecka J, Cierpicki T.

Blood. 2014 Dec 11;124(25):3730-7. doi: 10.1182/blood-2014-01-550079. Epub 2014 Oct 10.

24.

C/EBPα is an essential collaborator in Hoxa9/Meis1-mediated leukemogenesis.

Collins C, Wang J, Miao H, Bronstein J, Nawer H, Xu T, Figueroa M, Muntean AG, Hess JL.

Proc Natl Acad Sci U S A. 2014 Jul 8;111(27):9899-904. doi: 10.1073/pnas.1402238111. Epub 2014 Jun 23.

25.

From the guest editor: into the era of personalized cancer diagnostics.

Hess JL.

Cancer J. 2014 Jan-Feb;20(1):28. doi: 10.1097/PPO.0000000000000023. No abstract available.

PMID:
24445762
26.

Targeting MLL1 H3K4 methyltransferase activity in mixed-lineage leukemia.

Cao F, Townsend EC, Karatas H, Xu J, Li L, Lee S, Liu L, Chen Y, Ouillette P, Zhu J, Hess JL, Atadja P, Lei M, Qin ZS, Malek S, Wang S, Dou Y.

Mol Cell. 2014 Jan 23;53(2):247-61. doi: 10.1016/j.molcel.2013.12.001. Epub 2014 Jan 2.

27.

How might ZNF804A variants influence risk for schizophrenia and bipolar disorder? A literature review, synthesis, and bioinformatic analysis.

Hess JL, Glatt SJ.

Am J Med Genet B Neuropsychiatr Genet. 2014 Jan;165B(1):28-40. doi: 10.1002/ajmg.b.32207. Epub 2013 Oct 4. Review.

PMID:
24123948
28.

Targeting recruitment of disruptor of telomeric silencing 1-like (DOT1L): characterizing the interactions between DOT1L and mixed lineage leukemia (MLL) fusion proteins.

Shen C, Jo SY, Liao C, Hess JL, Nikolovska-Coleska Z.

J Biol Chem. 2013 Oct 18;288(42):30585-96. doi: 10.1074/jbc.M113.457135. Epub 2013 Sep 1.

29.

MLL fusion protein-driven AML is selectively inhibited by targeted disruption of the MLL-PAFc interaction.

Muntean AG, Chen W, Jones M, Granowicz EM, Maillard I, Hess JL.

Blood. 2013 Sep 12;122(11):1914-22. doi: 10.1182/blood-2013-02-486977. Epub 2013 Jul 30.

30.

MLL-ENL inhibits polycomb repressive complex 1 to achieve efficient transformation of hematopoietic cells.

Maethner E, Garcia-Cuellar MP, Breitinger C, Takacova S, Divoky V, Hess JL, Slany RK.

Cell Rep. 2013 May 30;3(5):1553-66. doi: 10.1016/j.celrep.2013.03.038. Epub 2013 Apr 25.

31.

A subset of mixed lineage leukemia proteins has plant homeodomain (PHD)-mediated E3 ligase activity.

Wang J, Muntean AG, Wu L, Hess JL.

J Biol Chem. 2012 Dec 21;287(52):43410-6. doi: 10.1074/jbc.M112.423855. Epub 2012 Nov 5.

32.

Twenty-first century pathology sign-out.

Tomlins S, Robinson D, Penny RJ, Hess JL.

Clin Lab Med. 2012 Dec;32(4):639-50. doi: 10.1016/j.cll.2012.07.002. Review.

PMID:
23078664
33.

Base-pair resolution DNA methylation sequencing reveals profoundly divergent epigenetic landscapes in acute myeloid leukemia.

Akalin A, Garrett-Bakelman FE, Kormaksson M, Busuttil J, Zhang L, Khrebtukova I, Milne TA, Huang Y, Biswas D, Hess JL, Allis CD, Roeder RG, Valk PJ, Löwenberg B, Delwel R, Fernandez HF, Paietta E, Tallman MS, Schroth GP, Mason CE, Melnick A, Figueroa ME.

PLoS Genet. 2012;8(6):e1002781. doi: 10.1371/journal.pgen.1002781. Epub 2012 Jun 21.

34.

Menin-MLL inhibitors reverse oncogenic activity of MLL fusion proteins in leukemia.

Grembecka J, He S, Shi A, Purohit T, Muntean AG, Sorenson RJ, Showalter HD, Murai MJ, Belcher AM, Hartley T, Hess JL, Cierpicki T.

Nat Chem Biol. 2012 Jan 29;8(3):277-84. doi: 10.1038/nchembio.773.

35.

ECSASB2 mediates MLL degradation during hematopoietic differentiation.

Wang J, Muntean AG, Hess JL.

Blood. 2012 Feb 2;119(5):1151-61. doi: 10.1182/blood-2011-06-362079. Epub 2011 Dec 15.

36.

CBX8, a polycomb group protein, is essential for MLL-AF9-induced leukemogenesis.

Tan J, Jones M, Koseki H, Nakayama M, Muntean AG, Maillard I, Hess JL.

Cancer Cell. 2011 Nov 15;20(5):563-75. doi: 10.1016/j.ccr.2011.09.008.

37.

Self-assembly of dinitrosyl iron units into imidazolate-edge-bridged molecular squares: characterization including Mössbauer spectroscopy.

Hess JL, Hsieh CH, Brothers SM, Hall MB, Darensbourg MY.

J Am Chem Soc. 2011 Dec 21;133(50):20426-34. doi: 10.1021/ja208384d. Epub 2011 Nov 29.

38.

Identification and characterization of Hoxa9 binding sites in hematopoietic cells.

Huang Y, Sitwala K, Bronstein J, Sanders D, Dandekar M, Collins C, Robertson G, MacDonald J, Cezard T, Bilenky M, Thiessen N, Zhao Y, Zeng T, Hirst M, Hero A, Jones S, Hess JL.

Blood. 2012 Jan 12;119(2):388-98. doi: 10.1182/blood-2011-03-341081. Epub 2011 Nov 9.

39.

The pathogenesis of mixed-lineage leukemia.

Muntean AG, Hess JL.

Annu Rev Pathol. 2012;7:283-301. doi: 10.1146/annurev-pathol-011811-132434. Epub 2011 Oct 17. Review.

40.

N-heterocyclic carbene ligands as mimics of imidazoles/histidine for the stabilization of di- and trinitrosyl iron complexes.

Hess JL, Hsieh CH, Reibenspies JH, Darensbourg MY.

Inorg Chem. 2011 Sep 5;50(17):8541-52. doi: 10.1021/ic201138f. Epub 2011 Aug 8.

PMID:
21823576
41.

Requirement for Dot1l in murine postnatal hematopoiesis and leukemogenesis by MLL translocation.

Jo SY, Granowicz EM, Maillard I, Thomas D, Hess JL.

Blood. 2011 May 5;117(18):4759-68. doi: 10.1182/blood-2010-12-327668. Epub 2011 Feb 25.

42.

PAFc, a key player in MLL-rearranged leukemogenesis.

Tan J, Muntean AG, Hess JL.

Oncotarget. 2010 Oct;1(6):461-5.

43.

Significance of AF4-MLL reciprocal fusion in t(4;11) leukemias?

Sanders DS, Muntean AG, Hess JL.

Leuk Res. 2011 Mar;35(3):299-300. doi: 10.1016/j.leukres.2010.09.015. Epub 2010 Oct 16. No abstract available.

PMID:
20952059
44.

Acute myeloid leukemia diagnosis in the 21st century.

Betz BL, Hess JL.

Arch Pathol Lab Med. 2010 Oct;134(10):1427-33. doi: 10.1043/2010-0245-RA.1. Review.

PMID:
20923295
45.

What are we anyway? The role of pathologists in the 21st century.

Hess JL.

Arch Pathol Lab Med. 2010 Oct;134(10):1424-6. doi: 10.1043/2010-0237-ED.1. No abstract available.

PMID:
20923294
46.

MLL-AF9 and MLL-ENL alter the dynamic association of transcriptional regulators with genes critical for leukemia.

Monroe SC, Jo SY, Sanders DS, Basrur V, Elenitoba-Johnson KS, Slany RK, Hess JL.

Exp Hematol. 2011 Jan;39(1):77-86.e1-5. doi: 10.1016/j.exphem.2010.09.003. Epub 2010 Sep 18.

47.

The PAF complex synergizes with MLL fusion proteins at HOX loci to promote leukemogenesis.

Muntean AG, Tan J, Sitwala K, Huang Y, Bronstein J, Connelly JA, Basrur V, Elenitoba-Johnson KS, Hess JL.

Cancer Cell. 2010 Jun 15;17(6):609-21. doi: 10.1016/j.ccr.2010.04.012.

48.

The role of menin in hematopoiesis.

Maillard I, Hess JL.

Adv Exp Med Biol. 2009;668:51-7.

49.

Loss-of-function Additional sex combs like 1 mutations disrupt hematopoiesis but do not cause severe myelodysplasia or leukemia.

Fisher CL, Pineault N, Brookes C, Helgason CD, Ohta H, Bodner C, Hess JL, Humphries RK, Brock HW.

Blood. 2010 Jan 7;115(1):38-46. doi: 10.1182/blood-2009-07-230698. Epub 2009 Oct 27.

50.

Additional sex combs-like 1 belongs to the enhancer of trithorax and polycomb group and genetically interacts with Cbx2 in mice.

Fisher CL, Lee I, Bloyer S, Bozza S, Chevalier J, Dahl A, Bodner C, Helgason CD, Hess JL, Humphries RK, Brock HW.

Dev Biol. 2010 Jan 1;337(1):9-15. doi: 10.1016/j.ydbio.2009.10.004. Epub 2009 Oct 13.

Supplemental Content

Support Center